{'52WeekChange': 0.14655459,
 'SandP52WeekChange': None,
 'address1': 'Semmelweisstrasse 7',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 32.75,
 'askSize': 800,
 'averageDailyVolume10Day': 73962,
 'averageVolume': 127487,
 'averageVolume10days': 73962,
 'beta': 1.173255,
 'beta3Year': None,
 'bid': 32.64,
 'bidSize': 800,
 'bookValue': 4.90275,
 'category': None,
 'circulatingSupply': None,
 'city': 'Planegg',
 'companyOfficers': [],
 'country': 'Germany',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 32.87,
 'dayLow': 32.42,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 4277709568,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '49 89 89927 222',
 'fiftyDayAverage': 32.26557,
 'fiftyTwoWeekHigh': 37.961,
 'fiftyTwoWeekLow': 18.21,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 126811749,
 'forwardEps': -3.23,
 'forwardPE': -10.136224,
 'fromCurrency': None,
 'fullTimeEmployees': 516,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.07159,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/morphosys.com',
 'longBusinessSummary': 'MorphoSys AG, together with its subsidiaries, '
                        'develops and commercializes antibodies and peptides '
                        'for therapeutic applications in the United States. '
                        'The company, together with its pharmaceutical '
                        'partners, develops a therapeutic pipeline of '
                        'approximately 115 drugs for various diseases, such as '
                        "psoriasis, Alzheimer's diseases, haematological "
                        'malignancies, solid tumors, hemophilia, multiple '
                        'myeloma, metabolic diseases, inflamation, thrombosis, '
                        'brittle bone syndrome, eye diseases, cancers, '
                        'diabetic eye diseases, blood disorders, and asthma. '
                        'Its product pipeline includes MOR208, an antibody for '
                        'the treatment of haematological cancers; MOR202, an '
                        'antibody for the treatment of multiple myeloma and '
                        'other cancers, as well as other autoimmune diseases; '
                        'MOR106, an antibody for rheumatoid arthritis; and '
                        'MOR107, a lanthipeptide for oncology diseases. '
                        'MorphoSys AG has a regional licensing agreement with '
                        'I-Mab Biopharma to develop and commercialize MOR202 '
                        'in China, Taiwan, Hong Kong, and Macao; a strategic '
                        'alliance with the LEO Pharma A/S to develop '
                        'peptide-derived therapeutics for unmet medical needs; '
                        'and a joint collaboration and license agreement with '
                        'Incyte Corporation for the development and '
                        "commercialization of MorphoSys' investigational "
                        'compound tafasitamab (MOR208). The company was '
                        'founded in 1992 and is headquartered in Planegg, '
                        'Germany.',
 'longName': 'MorphoSys AG',
 'market': 'us_market',
 'marketCap': 4349149184,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_135647',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 32.72,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '49 89 89927 0',
 'previousClose': 34.11,
 'priceHint': 2,
 'priceToBook': 6.677885,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0.37219003,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 32.87,
 'regularMarketDayLow': 32.42,
 'regularMarketOpen': 32.72,
 'regularMarketPreviousClose': 34.11,
 'regularMarketPrice': 32.72,
 'regularMarketVolume': 51048,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 130657000,
 'sharesPercentSharesOut': 0.0057,
 'sharesShort': 714637,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 721762,
 'shortName': 'MorphoSys AG',
 'shortPercentOfFloat': None,
 'shortRatio': 8.3,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'MOR',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.26075,
 'twoHundredDayAverage': 29.680431,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'e69ac107-9473-3ee4-815d-c7bb67c1cad3',
 'volume': 51048,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.morphosys.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '82152'}